Compare Inovio Pharmaceuticals Inc (INO) vs T Rowe Price Group Inc (TROW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs T Rowe Price Group Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $1.1 (market cap $112.19M), while T Rowe Price Group Inc trades at $104.25 (market cap $22.23B). The key difference: T Rowe Price Group Inc is far larger — about 198.1× Inovio Pharmaceuticals Inc's market cap, and T Rowe Price Group Inc pays a 4.99% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and T Rowe Price Group Inc for 115 Days on average.
| INO | TROW | |
|---|---|---|
Market Cap | $112.19M | $22.23B |
Volume | 3,201,278 | 2,834,949 |
Sector | Health | Financials |
52-Week High | $2.65 | $121.68 |
52-Week Low | $0.66 | $86.19 |
Typical Hold Time | 43 Days | 115 Days |
Enterprise Value | $83.51M | $19.43B |
Dividend Yield | — | 4.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Inovio Pharmaceuticals trades at $1.155, up 2.21% today, with a bearish technical signal despite recent earnings beats. The company faces significant fundamental challenges with minimal revenue of $65,340 and substantial losses, reflected in a -130,000% net margin. Key catalyst is the October 30, 2026 FDA decision on INO-3107 for recurrent respiratory papillomatosis, with analyst consensus leaning bullish at a $2.75 price target.
Investment outlook hinges on FDA approval success; upside exists if INO-3107 gains approval, but persistent cash burn and lack of commercial revenue pose substantial risks. The stock remains speculative with high volatility expected around regulatory milestones.
T. Rowe Price Group (TROW) trades at $104.07, up 0.45% with bearish technical signals but strong fundamentals including a 10.45 P/E ratio and 29.26% net margin. Recent earnings beat expectations in Q1 and Q2 2026, while Q4 2025 slightly missed. The company maintains robust cash flow with $704.4M net cash flow in 2025 and a dividend yield near 5% with 40 years of consecutive growth.
The stock offers value with attractive valuation metrics and consistent profitability, though technical indicators suggest near-term pressure. Key risks include market-sensitive revenue streams and net outflows, while analyst consensus at $112 target implies 7.6% upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About T Rowe Price Group Inc
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →
